[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MD4412C1 - Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis - Google Patents

Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis

Info

Publication number
MD4412C1
MD4412C1 MDA20140092A MD20140092A MD4412C1 MD 4412 C1 MD4412 C1 MD 4412C1 MD A20140092 A MDA20140092 A MD A20140092A MD 20140092 A MD20140092 A MD 20140092A MD 4412 C1 MD4412 C1 MD 4412C1
Authority
MD
Moldova
Prior art keywords
prevention
hypertensive
complications
genesis
ylmethyl
Prior art date
Application number
MDA20140092A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4412B1 (en
Inventor
Алёна ДУРНЯ
Александру КАРАУШ
Константин ЖУКОВСКИЙ
Original Assignee
Алёна ДУРНЯ
Александру КАРАУШ
Константин ЖУКОВСКИЙ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алёна ДУРНЯ, Александру КАРАУШ, Константин ЖУКОВСКИЙ filed Critical Алёна ДУРНЯ
Priority to MDA20140092A priority Critical patent/MD4412C1/en
Publication of MD4412B1 publication Critical patent/MD4412B1/en
Publication of MD4412C1 publication Critical patent/MD4412C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to cardiology and can be used in the complex treatment of patients with hypertension, to improve vascular elasticity in the prevention of severe complications as acute stroke, renal failure, hypertensive retinopathy, myocardial infarction.Summary of the invention consists in the use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis, which is administered per os, 600…1200 mg, once a day.
MDA20140092A 2014-08-29 2014-08-29 Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis MD4412C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20140092A MD4412C1 (en) 2014-08-29 2014-08-29 Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20140092A MD4412C1 (en) 2014-08-29 2014-08-29 Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis

Publications (2)

Publication Number Publication Date
MD4412B1 MD4412B1 (en) 2016-04-30
MD4412C1 true MD4412C1 (en) 2016-11-30

Family

ID=55911139

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140092A MD4412C1 (en) 2014-08-29 2014-08-29 Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis

Country Status (1)

Country Link
MD (1) MD4412C1 (en)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104115A2 (en) * 1982-09-21 1984-03-28 Thomson-Csf Viewer with instantaneous enlarged field comprising a mirror and method of manufacturing said mirror
WO2001076573A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
WO2002011723A1 (en) * 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
RU2195273C2 (en) * 1996-08-09 2002-12-27 БИОРЕКС Кутато еш Фейлесте Рт Pharmaceutical compounds for treatment and prophylaxis of diseases arising as result of damage of vascular endothelial cells
WO2005039639A2 (en) * 2003-10-10 2005-05-06 Solvay Pharmaceuticals Gmbh Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
RU2268046C1 (en) * 2004-05-31 2006-01-20 Илья Николаевич Медведев Method for normalizing thrombocytic disorders in case of metabolic syndrome
RU2271202C1 (en) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Method for correcting endothelial dysfunction
RU2272628C1 (en) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Method for rapid optimization of platelet function at metabolic syndrome
RU2272622C1 (en) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Method for correction of platelet membrane lipid composition and activity at metabolic syndrome
US20060194861A1 (en) * 2002-06-27 2006-08-31 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2006324324A (en) * 2005-05-17 2006-11-30 Sumitomo Electric Ind Ltd Light emitting device, method of manufacturing same, and semiconductor substrate
WO2007066678A1 (en) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjuctival disease
RU2333750C1 (en) * 2007-04-09 2008-09-20 Илья Николаевич Медведев Method of efficient nitrogen oxide level correlation in blood of patients with metabolic syndrome
RU2337681C1 (en) * 2007-04-09 2008-11-10 Илья Николаевич Медведев Method of accelerated normalisation of arachidonic acid platelet metabolism in patients suffering from metabolic syndrome
RU2338536C1 (en) * 2007-02-19 2008-11-20 Илья Николаевич Медведев Method of normalisation of functional abilities of thrombocytes at metabolic syndrome
RU2338520C1 (en) * 2007-02-28 2008-11-20 Илья Николаевич Медведев Method of correction of nitrogen oxide level in blood of patients with metabolic syndrome

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104115A2 (en) * 1982-09-21 1984-03-28 Thomson-Csf Viewer with instantaneous enlarged field comprising a mirror and method of manufacturing said mirror
RU2195273C2 (en) * 1996-08-09 2002-12-27 БИОРЕКС Кутато еш Фейлесте Рт Pharmaceutical compounds for treatment and prophylaxis of diseases arising as result of damage of vascular endothelial cells
WO2001076573A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
RU2298418C2 (en) * 2000-04-12 2007-05-10 Новартис Аг Combination of at least two compounds chosen from groups at1-receptor antagonists or inhibitors of ace (angiotensin-converting enzyme) or inhibitors of hmg-coa-reductase (beta-hydroxy-beta-methylglutaryl-coenzyme-a-reductase)
WO2002011723A1 (en) * 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
US20060194861A1 (en) * 2002-06-27 2006-08-31 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
WO2005039639A2 (en) * 2003-10-10 2005-05-06 Solvay Pharmaceuticals Gmbh Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
RU2362561C2 (en) * 2003-10-10 2009-07-27 Зольвай Фармасьютиклз Гмбх Pharmaceutical composition including selective agonist of imidazoline receptor i1 and blocker of angiotensin ii receptor
RU2268046C1 (en) * 2004-05-31 2006-01-20 Илья Николаевич Медведев Method for normalizing thrombocytic disorders in case of metabolic syndrome
RU2272622C1 (en) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Method for correction of platelet membrane lipid composition and activity at metabolic syndrome
RU2272628C1 (en) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Method for rapid optimization of platelet function at metabolic syndrome
RU2271202C1 (en) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Method for correcting endothelial dysfunction
JP2006324324A (en) * 2005-05-17 2006-11-30 Sumitomo Electric Ind Ltd Light emitting device, method of manufacturing same, and semiconductor substrate
WO2007066678A1 (en) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjuctival disease
RU2423127C2 (en) * 2005-12-06 2011-07-10 Сантен Фармасьютикал Ко., Лтд. Therapeutic medication against corneal-conjunctival disturbance
RU2338536C1 (en) * 2007-02-19 2008-11-20 Илья Николаевич Медведев Method of normalisation of functional abilities of thrombocytes at metabolic syndrome
RU2338520C1 (en) * 2007-02-28 2008-11-20 Илья Николаевич Медведев Method of correction of nitrogen oxide level in blood of patients with metabolic syndrome
RU2333750C1 (en) * 2007-04-09 2008-09-20 Илья Николаевич Медведев Method of efficient nitrogen oxide level correlation in blood of patients with metabolic syndrome
RU2337681C1 (en) * 2007-04-09 2008-11-10 Илья Николаевич Медведев Method of accelerated normalisation of arachidonic acid platelet metabolism in patients suffering from metabolic syndrome

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
LABIOS M et al. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension // Am J Hypertens. 2004 Sep; 17(9), p. 757-763 *
Morgan T., Lauri J., Bertram D., et al. Effect of different antihypertensive drug classes on central aortic pressure. Am. J. Hypertens, 2004, №17, p. 118-123 *
ORON-HERMAN M. et al. "Risk reduction therapy for syndrome X: comparison of several treatments". Am. J.Hypertens., 2005 Mar; 18(3), p. 372-378 *
SCRIBNER A.W. et al., The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress, Eur J Pharmacol. 2003б Dec 15; 482 (1-3), p. 95-99 *
ГАЛЕНКО Н.И. Способы немедикаментозной и фармакологической коррекции эндотелиальной дисфункции. ФАРМиндекс-практик, выпуск 10, 2006, с.2-10 *
ДЕМИДОВА Т.Ю. и др. Роль и место блокаторов ангиотензиновых рецепторов в коррекции компонентов метаболического синдрома у больных сахарным диабетом 2 типа. РМЖ 2005, т.13, №6, с.334-339 *
ЗАДИОНЧЕНКО В.С. и др. Артериальная гипертония при метаболическом синдроме: патогенез, основы терапии; Consilium medicum, т. 6, № 9, 2004 *
МАХНОВ Н.А. Эндотелиальная дисфункция: значение при атеросклерозе и методы ее определения, The First International Scientific Distance Conference «Cardiovascular Surgery and Angiology - 2003» Saint-Petersburg, Russia, December, 2003 *
ОГАНОВ Р.Г. Метаболические эффекты блокаторов рецепторов антиотензина II, НПЖ Кардиология, 2002, № 3, т.42, с.35-39 *
ЧАЗОВА И.Е. и др. Метаболический синдром, Media Medica, 2004, с.117-120, 130-132 *
ШТРЫГОЛЬ С.Ю. Блокаторы кальциевых каналов в кардиологии, ж. Провизор, выпуск № 6, 2004 *

Also Published As

Publication number Publication date
MD4412B1 (en) 2016-04-30

Similar Documents

Publication Publication Date Title
CL2016002132A1 (en) Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
MX2017008569A (en) Glucagon derivative having improved stability.
JP2016510326A5 (en)
CR20170320A (en) MIXTURE OF CARBOXYLIC ACIDS TO TREAT PATIENTS WITH RENAL INSUFFICIENCY
MY177393A (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
BR112017006690A8 (en) ALPHA-AMINOAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
MX2016007682A (en) Pharmaceutical composition comprising amorphous ivabradine.
MA39447A1 (en) (s) -pirlindole or its pharmaceutically acceptable salts for use in medicine
UY31790A (en) USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
MD4763C1 (en) Pharmaceutical composition
MD4412C1 (en) Use of 4-({2-butyl-5-[2-carboxy-2-(thiophene-2-ylmethyl)et-1-en-1-yl]-1H-imidazole-1-yl}methyl)benzoic acid to improve vascular elasticity in the prevention of complications of hypertensive genesis
AR077427A1 (en) OTAMIXABAN FOR THE TREATMENT OF PATIENTS WITH RENAL ALTERATION AND ADVANCED AGE WITH INFARTO OF MIOCARDIO WITHOUT ELEVATION OF THE ST
CO2018009543A2 (en) Extended release pharmaceutical composition comprising cysteamine or salt thereof
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
BR112017015840A2 (en) Method of treating or preventing atherothrombotic events in patients with a history of myocardial infarction
PL414785A1 (en) 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance
UA111785C2 (en) A COMPOSITION FOR THE TREATMENT OF Warts And A WAY OF TREATMENT
MY192061A (en) Pharmaceutical composition for external use
UA92408U (en) Cream intended for patients with syndrome of diabetic foot
EA201892048A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGAGLIFLOZIN, AND ITS APPLICATIONS
Cowan Fusidic acid/rosuvastatin interaction
Cohen Rivaroxaban of no net clinical benefit in critically ill patients
UY32985A (en) USE OF CELIVARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF CELIVARONA
PL422978A1 (en) Pergolide to be applied in treatment of eye diseases connected with increased level of vascular endothelial growth factor (VEGF) and the pergolid-containing pharmaceutical composition
UA103788U (en) Method for treatment of acute coronary syndrome without st-segment elevation in patients with ischemic heart disease and metabolic syndrome following percutaneous transluminar coronary angioplasty

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees